Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta‑blocker and a prostaglandin analog presented as an ophthalmic solution for topical eye use. They lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family. - Open‑angle glaucoma: reduces intra‑ocular pressure to help preserve visual fields. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Secondary glaucoma: assists in controlling pressure when caused by other ocular conditions. - Post‑surgical ocular pressure management: helps maintain target pressure after glaucoma surgery.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision - Ocular hyperemia (redness) - Dry eye or foreign‑body sensation - Headache - Transient visual disturbances

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Ocular inflammation or uveitis - Systemic bradycardia or hypotension - Bronchospasm or asthma exacerbation - Worsening of chronic obstructive pulmonary disease - Macular edema, especially in diabetic patients

Before initiating therapy, evaluate the patient’s cardiovascular and respiratory status. - Cardiovascular disease: monitor heart rate and blood pressure due to beta‑blocker effects. - Respiratory conditions: avoid in patients with asthma or severe COPD. - Ocular inflammation: contraindicated in active uveitis or ocular infections. - Pregnancy and lactation: use only if potential benefit justifies risk. - Drug interactions: review concomitant systemic beta‑blockers or prostaglandin analogues. - Store at room temperature: keep in the original container, protect from light, and do not freeze.

Major Interactions (Avoid): - Systemic beta‑blockers (e.g., propranolol): may cause additive bradycardia or hypotension. - Non‑selective beta‑blocker eye drops: increase risk of systemic beta‑blockade. - Asthma medications (e.g., beta‑agonists): may reduce efficacy and increase bronchospasm risk.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors (oral or topical): additive intra‑ocular pressure reduction. - Other prostaglandin analogues: may increase ocular hyperemia. - Anticholinergic eye drops: could diminish timolol’s IOP‑lowering effect. - NSAID eye drops: may affect ocular surface tolerance.